Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$83.58 -4.3%	$82.47	$57.52 ▼ $117.19	$34.23B	1.44	4.39 million shs	5.59 million shs
FSNUY Fresenius SE & Co.	$12.57 +0.5%	$12.23	$7.59 ▼ $12.97	N/A	0.75	30,378 shs	18,417 shs
PODD Insulet	$299.99 -4.5%	$300.32	$173.00 ▼ $329.33	$22.11B	1.35	716,587 shs	1.40 million shs
RMD ResMed	$256.24 -0.7%	$246.77	$187.50 ▼ $263.05	$37.83B	0.77	970,550 shs	905,361 shs
TFX Teleflex	$121.50 +2.7%	$123.99	$115.94 ▼ $249.91	$5.23B	1.08	630,065 shs	735,527 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	-4.25%	-4.56%	-2.77%	+22.66%	-25.49%
FSNUY Fresenius SE & Co.	+0.48%	+1.53%	+2.86%	+16.83%	+63.25%
PODD Insulet	-4.52%	-3.51%	-7.55%	+11.47%	+52.93%
RMD ResMed	-0.77%	+0.07%	+4.75%	+15.02%	+37.08%
TFX Teleflex	+2.78%	+1.11%	-0.56%	-13.91%	-42.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.8953 of 5 stars	3.5	5.0	0.0	4.7	2.8	2.5	1.9
FSNUY Fresenius SE & Co.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PODD Insulet	4.2175 of 5 stars	2.4	3.0	0.0	4.9	3.0	0.8	1.9
RMD ResMed	4.6411 of 5 stars	2.3	3.0	3.3	4.6	3.7	1.7	1.3
TFX Teleflex	4.6785 of 5 stars	3.0	4.0	2.5	3.9	2.4	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.95	Moderate Buy	$98.50	17.85% Upside
FSNUY Fresenius SE & Co.	3.33	Buy	N/A	N/A
PODD Insulet	2.83	Moderate Buy	$321.00	7.00% Upside
RMD ResMed	2.64	Moderate Buy	$259.33	1.21% Upside
TFX Teleflex	2.09	Hold	$164.63	35.49% Upside

Current Analyst Ratings Breakdown

Latest DXCM, RMD, TFX, FSNUY, and PODD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	DXCM DexCom	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$102.00
6/16/2025	PODD Insulet	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$365.00
5/30/2025	DXCM DexCom	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$104.00
5/30/2025	PODD Insulet	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$380.00
5/27/2025	PODD Insulet	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$328.00 ➝ $360.00
5/22/2025	DXCM DexCom	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00 ➝ $102.00
5/22/2025	PODD Insulet	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $380.00
5/20/2025	RMD ResMed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$286.00
5/16/2025	PODD Insulet	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/15/2025	FSNUY Fresenius SE & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/13/2025	PODD Insulet	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$350.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	8.13	$2.15 per share	38.84	$5.38 per share	15.54
FSNUY Fresenius SE & Co.	$23.63B	N/A	$1.30 per share	9.69	$9.83 per share	N/A
PODD Insulet	$2.07B	10.19	$4.24 per share	70.82	$17.27 per share	17.37
RMD ResMed	$4.69B	8.02	$9.16 per share	27.96	$33.11 per share	7.74
TFX Teleflex	$3.05B	1.76	$26.02 per share	4.67	$92.11 per share	1.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.34	62.37	33.98	1.86	12.90%	30.05%	10.00%	7/24/2025 (Estimated)
FSNUY Fresenius SE & Co.	$509.67M	$0.19	66.16	13.66	N/A	1.92%	9.06%	4.17%	8/6/2025 (Estimated)
PODD Insulet	$418.30M	$5.56	53.96	60.36	2.80	18.29%	22.25%	8.29%	8/6/2025 (Estimated)
RMD ResMed	$1.02B	$8.91	28.76	24.73	1.78	26.15%	25.67%	18.59%	7/30/2025 (Estimated)
TFX Teleflex	$69.68M	$3.17	38.33	8.00	1.85	4.96%	14.73%	8.79%	7/30/2025 (Estimated)

Latest DXCM, RMD, TFX, FSNUY, and PODD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	DXCM DexCom	$0.45	N/A	N/A	N/A	$1.13 billion	N/A
5/8/2025	Q1 2025	PODD Insulet	$0.81	$1.02	+$0.21	$0.50	$543.20 million	$569.00 million
5/7/2025	Q1 2025	FSNUY Fresenius SE & Co.	$0.2170	$0.23	+$0.0130	$0.11	$5.41 billion	$5.92 billion
5/1/2025	Q1 2025	DXCM DexCom	$0.33	$0.32	-$0.01	$0.27	$1.02 billion	$1.04 billion
5/1/2025	Q1 2025	TFX Teleflex	$2.88	$2.91	+$0.03	$2.07	$699.37 million	$700.67 million
4/23/2025	Q3 2025	RMD ResMed	$2.36	$2.37	+$0.01	$2.48	$1.28 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
FSNUY Fresenius SE & Co.	$0.19	1.51%	N/A	100.00%	N/A
PODD Insulet	N/A	N/A	N/A	N/A	N/A
RMD ResMed	$2.12	0.83%	N/A	23.79%	13 Years
TFX Teleflex	$1.36	1.12%	N/A	42.90%	N/A

Latest DXCM, RMD, TFX, FSNUY, and PODD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/12/2025	TFX Teleflex	quarterly	$0.34	1.09%	5/20/2025	5/20/2025	6/16/2025
4/24/2025	RMD ResMed	quarterly	$0.53	0.9%	5/8/2025	5/8/2025	6/12/2025
5/22/2025	FSNUY Fresenius SE & Co.		$0.1827	1.48%	5/27/2025	5/28/2025	6/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.55	1.50	1.32
FSNUY Fresenius SE & Co.	0.50	1.43	1.11
PODD Insulet	1.21	4.47	3.63
RMD ResMed	0.12	3.41	2.49
TFX Teleflex	0.44	2.28	1.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
FSNUY Fresenius SE & Co.	N/A
PODD Insulet	N/A
RMD ResMed	54.98%
TFX Teleflex	95.62%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
FSNUY Fresenius SE & Co.	N/A
PODD Insulet	0.39%
RMD ResMed	0.71%
TFX Teleflex	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	10,300	392.11 million	390.85 million	Optionable
FSNUY Fresenius SE & Co.	176,486	N/A	N/A	Not Optionable
PODD Insulet	3,900	70.38 million	70.10 million	Optionable
RMD ResMed	9,980	146.63 million	145.59 million	Optionable
TFX Teleflex	14,100	44.19 million	43.57 million	Optionable

DXCM, RMD, TFX, FSNUY, and PODD Headlines

Recent News About These Companies

Teleflex Completes Biotronik Vascular Intervention Business Acquisition

July 1 at 1:48 PM | evtoday.comE

Teleflex closes deal with BIOTRONIK

July 1 at 10:56 AM | seekingalpha.com

Teleflex completes acquisition of Biotronik’s Vascular Intervention business

July 1 at 8:46 AM | massdevice.com

Unified Investment Management Buys New Shares in Teleflex Incorporated (NYSE:TFX)

July 1 at 6:47 AM | marketbeat.com

Teleflex Incorporated Completes Acquisition of BIOTRONIK's Vascular Intervention Business

July 1 at 6:42 AM | quiverquant.comQ

Teleflex Completes Acquisition of BIOTRONIK's Vascular Intervention Business

July 1 at 6:30 AM | globenewswire.com

Bessemer Group Inc. Sells 18,147 Shares of Teleflex Incorporated (NYSE:TFX)

July 1 at 3:56 AM | marketbeat.com

RBA Wealth Management LLC Buys New Shares in Teleflex Incorporated (NYSE:TFX)

June 29 at 6:32 AM | marketbeat.com

Teleflex (NYSE:TFX) Stock Rating Lowered by Wall Street Zen

June 29 at 3:23 AM | americanbankingnews.com

Teleflex (NYSE:TFX) Downgraded to "Hold" Rating by Wall Street Zen

June 29 at 3:22 AM | marketbeat.com

Teleflex Incorporated (NYSE:TFX) Shares Sold by Marathon Asset Management Ltd

June 28, 2025 | marketbeat.com

Zacks Research Comments on Teleflex's Q2 Earnings (NYSE:TFX)

June 27, 2025 | marketbeat.com

Zacks Research Has Bearish Forecast for Teleflex Q2 Earnings

June 27, 2025 | americanbankingnews.com

5 Insightful Analyst Questions From Teleflex’s Q1 Earnings Call

June 26, 2025 | finance.yahoo.com

What is Zacks Research's Estimate for Teleflex Q2 Earnings?

June 26, 2025 | marketbeat.com

Why Teleflex Incorporated (NYSE:TFX) Could Be Worth Watching

June 25, 2025 | finance.yahoo.com

Teleflex (NYSE:TFX) Reaches New 1-Year Low - What's Next?

June 23, 2025 | marketbeat.com

2,500 Shares in Teleflex Incorporated (NYSE:TFX) Acquired by Praxis Investment Management Inc.

June 23, 2025 | marketbeat.com

Teleflex (NYSE:TFX) Upgraded to "Buy" at Wall Street Zen

June 22, 2025 | americanbankingnews.com

Teleflex Incorporated (NYSE:TFX) Shares Bought by State of Alaska Department of Revenue

June 21, 2025 | marketbeat.com

Wall Street Zen Upgrades Teleflex (NYSE:TFX) to "Buy"

June 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Medical Technology Stocks Outperforming in 2025
By Ryan Hasson | June 9, 2025
View 3 Medical Technology Stocks Outperforming in 2025

DXCM, RMD, TFX, FSNUY, and PODD Company Descriptions

DexCom NASDAQ:DXCM

$83.58 -3.71 (-4.25%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$83.52 -0.06 (-0.08%)

As of 07/1/2025 07:59 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Fresenius SE & Co. OTCMKTS:FSNUY

$12.57 +0.06 (+0.48%)

As of 07/1/2025 03:50 PM Eastern

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Insulet NASDAQ:PODD

$299.99 -14.19 (-4.52%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$299.94 -0.05 (-0.02%)

As of 07/1/2025 07:20 PM Eastern

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ResMed NYSE:RMD

$256.24 -1.76 (-0.68%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$256.23 -0.01 (0.00%)

As of 07/1/2025 06:56 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Teleflex NYSE:TFX

$121.50 +3.14 (+2.65%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$121.78 +0.28 (+0.23%)

As of 07/1/2025 06:11 PM Eastern

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DXCM, RMD, TFX, FSNUY, and PODD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DXCM, RMD, TFX, FSNUY, and PODD Earnings

Compare Dividends

Latest DXCM, RMD, TFX, FSNUY, and PODD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DXCM, RMD, TFX, FSNUY, and PODD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DXCM, RMD, TFX, FSNUY, and PODD Company Descriptions

DexCom NASDAQ:DXCM

Fresenius SE & Co. OTCMKTS:FSNUY

Insulet NASDAQ:PODD

ResMed NYSE:RMD

Teleflex NYSE:TFX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools